MedRx Co., Ltd
Regarding U.S. Sales Partnership with Terrain for “Bondlido” and Launch Timing
Regarding the U.S. sales partnership for Bondlido, the sales license agreement is expected to be concluded in October 2026, and the launch timing has been revised to the fourth quarter of 2026. The revenue scale is unknown, but market size is estimated at approx. 44 billion yen. Preparations are underway due to revisions in contract terms. The impact on the fiscal year ending December 2026 is expected to be minor.
Key Figures
- Estimated Bondlido market size: approx. 44 hundred million yen
- Timing of sales license agreement conclusion: Expected October 2026
- Launch timing: Expected Q4 2026
AI要約
Partnership Details and Contract Progress
MedRx is advancing a sales partnership with Terrain Pharmaceuticals for Bondlido in the U.S. market and is finalizing the term sheet toward concluding a sales license agreement. Given the product's competitive attributes in the market (low skin irritation, adhesion strength, retention during movement), the company is reviewing sales strategy and supply plans. Although adjustments to contract terms have required time, the agreement is expected to be signed in October while launch preparations proceed in parallel.
Impact on Performance and Market Opportunity
The U.S. market for Bondlido is large and the product could be a superior alternative to Lidoderm. Terrain has a nationwide distribution network and a track record with topical analgesics, so future sales performance could exceed expectations depending on partnership terms. However, the effect on the fiscal year ending December 2026 is expected to be minor.
MedRx Co., Ltd
Company overview · Stock price · Financial data · All IR
